contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-sedana-medicals-interim-report-for-the-fourth-quarter-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Sedana Medical operates in the medical technology industry and focuses on the development and manufacture of systems for inhalation anesthesia. The company's products are aimed at healthcare institutions and anesthesiologists. The business is global with a main presence in Europe, North America and Asia. Sedana Medical was founded in 2005 and is headquartered in Danderyd, Sweden.

The figures can be found in this latest interim report. Q2 / 2025 was a slightly weaker-than-expected quarter, which at least for a moment scared investors.            storage.mfn.se              sedana-medical-interim-report-q225.pdf

Sedana Medical AB doesn’t have its own thread, although I believe it’s on many investors’ radar or even in their portfolios, at least if they are focused on medtech stocks. The company was founded in 2005 and its headquarters are in Stockholm. The company specializes in sedation and aims to facilitate and even partially revolutionize intensive care by applying a lighter, non-invasive method for patient sedation through inhaled sedation. The product’s advantages include easier patient control and lighter, less invasive treatment. At the same time, it is evident that this is in some places a cheaper and more effective treatment method, but on the other hand, this treatment model cannot be applied to all patients. On the one hand, the company is in a mature phase in that it generates revenue, just under four million euros per quarter, but on the other hand, it is in a development phase in the sense that its EBITDA is -4%. It has just over 10 million euros in cash, and the burn rate in the last quarter was approximately three million euros. I initially entered this investment with a so-called observation position, because the company’s product, especially during the COVID years, felt very timely and interesting. Unfortunately, the company’s cash flow is still weak, and sales have not quite met the wildest expectations. Therefore, from a financing perspective, the company is likely still dependent on share issues, and it is difficult to form a clear understanding of future stock price development. On the other hand, precisely at this stage, after a somewhat soft quarterly report, it might be a good time to invest in the stock of this intensive care-revolutionizing company. Hopefully, the medtech experts in the Inderes community can contribute to analyzing this uncut diamond. In any case, investors are in good company, as the largest owner is the long-term experienced medtech investor Bengt Julander with a 13.6% stake; ownership is otherwise diversified. At worst / best, this promising early-stage company might fall into the lap of a larger entity at a good price, but of course, the most interesting outcome would be to secure a good long-term investment from this.

Sedana Medical

Sedana Medical AB (publ) plans to present its interim report for the fourth quarter of 2025 on Thursday February 12 at 13:30 CET.According to the financial calendar, Sedana Medical plans to ...

<div class="mfn-preamble"><p><strong>Sedana Medical AB (publ) plans to present its interim report for the fourth quarter of 2025 on Thursday February 12 at 13:30 CET.</strong></p></div><div class="mfn-body"><p>According to the financial calendar, Sedana Medical plans to publish the interim report for the fourth quarter 2025 on Thursday February 12 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Johan Spetz, CFO, and Peter Sackey, CMO, as well as answer questions.</p><p>Date: Thursday, February 12, 2026<br>Time (CET): 13:30</p><p>More info and link to the audiocast: <a rel="noopener" href="https://www.finwire.tv/webcast/sedana-medical/year-end-report-2025/">https://www.finwire.tv/webcast/sedana-medical/year-end-report-2025/</a></p><p>If you wish to participate via teleconference: +46 8505 39728. Meeting ID: 883 4763 0883 followed by #.</p><p>Welcome!</p></div><div class="mfn-footer mfn-contacts mfn-def614b69e2e"><p><strong class="mfn-heading-1">For additional information, please contact:</strong></p><hr><p>Johannes Doll, CEO, +46 (0)76 303 66 66<br>Johan Spetz, CFO, +46 (0)730 36 37 89<br>ir@sedanamedical.com</p></div><div class="mfn-footer mfn-about mfn-098844b56a8b"><p><strong class="mfn-heading-1">About Sedana Medical</strong></p><hr><p>Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.</p><p>Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.</p><p>Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/048d90d6-243c-44cc-8379-0d898d195644/invitation-to-presentation-of-sedana-medicals-interim-report-for-the-fourth-quarter-2025.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Sedana Medical’s interim report for the fourth quarter 2025</a></p></div>